12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cysteamine bitartrate regulatory update

FDA accepted for review an NDA from Raptor for RP103 to treat nephropathic cystinosis. The company had requested Priority Review, but FDA assigned the product a standard...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >